Attached files
| file | filename |
|---|---|
| EX-2.1 - EX-2.1 - AMICUS THERAPEUTICS, INC. | a14-5772_1ex2d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 2)
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 7, 2013
AMICUS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of
Incorporation)
|
001-33497 |
|
71-0869350 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
1 Cedar Brook Drive, Cranbury, NJ |
|
08512 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (609) 662-2000
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Explanatory Note
This Amendment No. 2 on Form 8-K/A is being filed solely to amend the Current Report on Form 8-K filed by Amicus Therapeutics, Inc. (“Amicus”) on November 21, 2013 (the “Original 8-K”), as amended by Amendment No. 1 on Form 8-K/A (“Amendment No. 1”), filed on February 4, 2014, to include, as an exhibit under Item 9.01, the Agreement and Plan of Merger, dated November 19, 2013, by and among Amicus, CB Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Amicus, Callidus Biopharma, Inc., a Delaware corporation, and Cuong Do, as holder representative.
|
Item 9.01. |
Financial Statements and Exhibits. |
a) Exhibits.
|
2.1* |
|
Agreement and Plan of Merger, dated November 19, 2013, by and among Amicus Therapeutics, Inc., CB Acquisition Corp., Callidus Biopharma, Inc. and Cuong Do. |
* Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that Amicus may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Amicus Therapeutics, Inc. | |
|
|
| |
|
|
| |
|
Date: February 12, 2014 |
By: |
/s/ William D. Baird III |
|
|
|
William D. Baird III |
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
|
|
|
|
2.1* |
|
Agreement and Plan of Merger, dated November 19, 2013, by and among Amicus Therapeutics, Inc., CB Acquisition Corp., Callidus Biopharma, Inc. and Cuong Do. |
* Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that Amicus may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.